Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús F. San Miguel(Instituto de Investigación Biomédica de Salamanca), Katja Weisel(University Children's Hospital Tübingen), Philippe Moreau, Martha Q. Lacy(Mayo Clinic), Kevin Song(Vancouver General Hospital), Michel Delforge(KU Leuven), Lionel Karlin(Hôpital Lyon Sud), Hartmut Goldschmidt(University Hospital Heidelberg), Anne Banos(Centre Hospitalier de la Côte Basque), Albert Oriol(Institut Català d'Oncologia), Adrían Alegre(Hospital Universitario de La Princesa), Christine Chen(Princess Margaret Cancer Centre), Michèle Cavo, Laurent Garderet(Hôpital Saint-Antoine), Valentina Ivanova(City Clinical Hospital), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Andrew R. Belch(University of Alberta), Antonio Palumbo(University of Turin), Stephen Schey(King's College Hospital), Pieter Sonneveld(Erasmus MC), Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios Α. Dimopoulos(Alexandra Hospital)
Cited by 796Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis